Sino Biopharmaceutical Limited (SEHK: 1177), known as Sino Biopharm, is a leading research and development-driven pharmaceutical conglomerate headquartered in Hong Kong. Founded in 2000 and listed on the Hong Kong Stock Exchange, the company develops, manufactures, and markets biopharmaceuticals, modernized Chinese medicines, and chemical drugs primarily in China.
Its portfolio targets key therapeutic areas including oncology, hepatology, respiratory diseases, cardiovascular conditions, and others such as tumors, liver diseases, and surgery/analgesia. Major subsidiaries include Chia Tai Tianqing Pharmaceutical Group and invoX Pharma. With a focus on innovation, Sino Biopharm maintains advanced R&D platforms and production facilities across China.
To provide comprehensive coverage, we aggregate data and news under the name Sino Biopharm, encompassing the following company names, divisions, and related entities:
中国生物制药有限公司.
This list encompasses current and former names, alternate names, and key divisions associated with Sino Biopharm, ensuring you can easily find all relevant information under a single, unified profile.
